The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | The future of immunotherapies in the CTCL treatment landscape
Due to the chronic nature of CTCL, chemotherapy is not a suitable option for patients. Francine Foss, MD, Yale University School of Medicine, New Haven, CT, describes potential non-chemotherapy treatment options for patients with cutaneous T-cell lymphoma (CTCL). Monoclonal antibodies such as the anti-CC chemokine receptor 4 (CCR4) mogamulizumab have proven to be more efficacious than vorinostat and is easier to administer, especially in the backdrop of the COVID-19 pandemic. Chimeric antigen receptor (CAR) T-cell therapies such as ones that target CD17 and CD30 additionally represent a new class of promising therapies for patients with CTCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
